XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Unaudited Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Accumulated deficit
Total
Beginning balance (in shares) at Dec. 31, 2023 40,609,915      
Beginning balance at Dec. 31, 2023 $ 40 $ 271,594 $ (245,102) $ 26,532
Stockholders' (Deficit) Equity        
Exercise of stock options (in shares) 1,579      
Exercise of stock options   2   2
Stock-based compensation   1,057   1,057
Sale of common stock under Open Market Sale Agreement, net of issuance costs (in shares) 931,250      
Sale of common stock under Open Market Sale Agreement, net of issuance costs $ 1 2,281   2,282
Net income (loss)     (18,978) (18,978)
Ending balance (in shares) at Mar. 31, 2024 41,542,744      
Ending balance at Mar. 31, 2024 $ 41 274,934 (264,080) 10,895
Beginning balance (in shares) at Dec. 31, 2023 40,609,915      
Beginning balance at Dec. 31, 2023 $ 40 271,594 (245,102) 26,532
Stockholders' (Deficit) Equity        
Net income (loss)       (42,842)
Ending balance (in shares) at Sep. 30, 2024 41,750,109      
Ending balance at Sep. 30, 2024 $ 41 276,777 (287,944) (11,126)
Beginning balance (in shares) at Mar. 31, 2024 41,542,744      
Beginning balance at Mar. 31, 2024 $ 41 274,934 (264,080) 10,895
Stockholders' (Deficit) Equity        
Exercise of stock options (in shares) 2,231      
Exercise of stock options   2   2
Stock-based compensation   625   625
Net income (loss)     (11,162) (11,162)
Ending balance (in shares) at Jun. 30, 2024 41,544,975      
Ending balance at Jun. 30, 2024 $ 41 275,561 (275,242) 360
Stockholders' (Deficit) Equity        
Stock-based compensation   1,115   1,115
Sale of common stock under Open Market Sale Agreement, net of issuance costs (in shares) 205,134      
Sale of common stock under Open Market Sale Agreement, net of issuance costs   101   101
Net income (loss)     (12,702) (12,702)
Ending balance (in shares) at Sep. 30, 2024 41,750,109      
Ending balance at Sep. 30, 2024 $ 41 276,777 (287,944) $ (11,126)
Beginning balance (in shares) at Dec. 31, 2024 41,750,109     41,750,109
Beginning balance at Dec. 31, 2024 $ 41 277,629 (305,579) $ (27,909)
Stockholders' (Deficit) Equity        
Exercise of stock options (in shares) 37,987      
Exercise of stock options   5   5
Stock-based compensation   508   508
Net income (loss)     (9,266) (9,266)
Ending balance (in shares) at Mar. 31, 2025 41,788,096      
Ending balance at Mar. 31, 2025 $ 41 278,142 (314,845) $ (36,662)
Beginning balance (in shares) at Dec. 31, 2024 41,750,109     41,750,109
Beginning balance at Dec. 31, 2024 $ 41 277,629 (305,579) $ (27,909)
Stockholders' (Deficit) Equity        
Exercise of stock options (in shares)       37,987
Net income (loss)       $ 25,677
Ending balance (in shares) at Sep. 30, 2025 41,788,096     41,788,096
Ending balance at Sep. 30, 2025 $ 41 278,994 (279,902) $ (867)
Beginning balance (in shares) at Mar. 31, 2025 41,788,096      
Beginning balance at Mar. 31, 2025 $ 41 278,142 (314,845) (36,662)
Stockholders' (Deficit) Equity        
Stock-based compensation   431   431
Net income (loss)     (9,774) (9,774)
Ending balance (in shares) at Jun. 30, 2025 41,788,096      
Ending balance at Jun. 30, 2025 $ 41 278,573 (324,619) (46,005)
Stockholders' (Deficit) Equity        
Stock-based compensation   421   421
Net income (loss)     44,717 $ 44,717
Ending balance (in shares) at Sep. 30, 2025 41,788,096     41,788,096
Ending balance at Sep. 30, 2025 $ 41 $ 278,994 $ (279,902) $ (867)